206989-41-5

Basic information

• Product Name: 5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-PROPYLAMINE
• Synonyms: 5,6,7,8-Tetrahydro-1,8-naphthyridin-2-propylamine;1,8-Naphthyridine-2-propanamine, 5,6,7,8-tetrahydro-;8-Naphthyridin-2-propylaMine;3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propan-1-aMine;5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-PROPYLAMINE 2HCL
• CAS NO: 206989-41-5
• Molecular Formula: C₁₁H₁₇N₃
• Molecular Weight: 191.27
• Mol File: 206989-41-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 66-68.5 °C
• Boiling Point: 359.026°C at 760 mmHg
• Flash Point: 170.933°C
• Appearance: /
• Density: 1.071g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.558
• PKA: 10.81±0.10(Predicted)
• CAS DataBase Reference: 5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-PROPYLAMINE(206989-41-5)
• EPA Substance Registry System: 5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-PROPYLAMINE(206989-41-5)

Safety Data

• Hazardous Substances Data: 206989-41-5(Hazardous Substances Data)

Usage

General Description

5,6,7,8-Tetrahydro-1,8-Naphthyridin-2-propylamine, also known as THNPA, is a chemical compound with the molecular formula C14H19N3. It is a tetrahydro-1,8-naphthyridine derivative, characterized by a propylamine substituent at the 2-position. THNPA is a heterocyclic compound with potential pharmaceutical applications due to its diverse biological activities. It has been studied for its potential as a therapeutic agent in the treatment of various diseases, including neurological disorders and cancer. The chemical structure and properties of 5,6,7,8-Tetrahydro-1,8-Naphthyridin-2-propylamine make it an important molecule for further research and potential development of new drugs.

InChI:InChI=1/C11H17N3/c12-7-1-4-10-6-5-9-3-2-8-13-11(9)14-10/h5-6H,1-4,7-8,12H2,(H,13,14)

Upstream product

• 85909-08-6 tert-butyl 2-oxopyrrolidine-1-carboxylate 
• 359883-38-8 2,2'-[pyridine-2,5-diylbis(propane-3,1-diyl)]bis(1H-isoindole-1,3(2H)-dione) 
• 227751-85-1 tert-butyl (3-(1,8-naphthyridin-2-yl)propyl)carbamate 
• 342648-58-2 dimethyl 5-[(tert-butoxycarbonyl)amino]-2-oxopentylphosphonate 
• 339555-33-8 3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile 
• 204452-91-5 3(S)-(6-methoxypyridin-3-yl)-3-alanine tert-butyl ester p-toluenesulfonic acid 
• 204452-90-4 2-(dimethoxymethyl)-1,8-naphthyridine 
• 204452-93-7 5,6,7,8-tetrahydro-[1,8]naphthyridine-2-carboxaldehyde 
• 7521-41-7 2-Aminonicotinaldehyde 
• 479401-00-8 N-(3-{5-[3-(formamido)prop-1-ynyl]pyridin-2-yl}prop-2-ynyl)formamide 
• 479401-02-0 [pyridine-2,5-diylbis(propane-3,1-diyl)]diformamide 
• 227751-86-2 tert-butyl (3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)carbamate 
• 339555-31-6 3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)prop-2-enenitrile 
• 359883-40-2 3-[5-(3-aminopropyl)pyridin-2-yl]propylamine 

Downstream Products

• 227963-15-7 (S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid 

Relevant articles and documents

A highly efficient synthesis of 2-[3-aminopropyl]-5,6,7,8-tetrahydronaphthyridine via a double Suzuki reaction and a Chichibabin cyclization

Synthesis of 2-[3-aminopropyl]-5,6,7,8-tetrahydronaphthyridine was accomplished via a one-pot double Suzuki reaction followed by deprotection and a highly regioselective intramolecular Chichibabin cyclization. A variety of reactions conditions were screened for the Chichibabin cyclization including choice of base, solvent and reaction temperature.

COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administrat

Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives

The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.